[go: up one dir, main page]

MX2010005099A - Usos de anticuerpos anti-cd40. - Google Patents

Usos de anticuerpos anti-cd40.

Info

Publication number
MX2010005099A
MX2010005099A MX2010005099A MX2010005099A MX2010005099A MX 2010005099 A MX2010005099 A MX 2010005099A MX 2010005099 A MX2010005099 A MX 2010005099A MX 2010005099 A MX2010005099 A MX 2010005099A MX 2010005099 A MX2010005099 A MX 2010005099A
Authority
MX
Mexico
Prior art keywords
chop
antibodies
treatment
rituximab
combination
Prior art date
Application number
MX2010005099A
Other languages
English (en)
Inventor
Mohammad Luqman
Yongyu Wang
Seema Kantak
Ssucheng J Hsu
Amer M Mirza
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010005099A publication Critical patent/MX2010005099A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a nuevos usos de anticuerpos anti-CD40 en el tratamiento de enfermedades y condiciones asociadas con el crecimiento de células B neoplásicas. La invención es particularmente útil para el tratamiento de pacientes quiénes han sido previamente administrados con (i) CHOP; (ii) el rituximab del anticuerpo monoclonal anti-CD20 quimérico o (iii) terapia por combinación con CHOP y rituximab.
MX2010005099A 2007-11-09 2008-11-07 Usos de anticuerpos anti-cd40. MX2010005099A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US254507P 2007-11-09 2007-11-09
PCT/US2008/082826 WO2009062054A1 (en) 2007-11-09 2008-11-07 Uses of anti-cd40 antibodies

Publications (1)

Publication Number Publication Date
MX2010005099A true MX2010005099A (es) 2010-05-27

Family

ID=40289413

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005099A MX2010005099A (es) 2007-11-09 2008-11-07 Usos de anticuerpos anti-cd40.

Country Status (11)

Country Link
US (1) US20110002934A1 (es)
EP (1) EP2211902A1 (es)
JP (1) JP5559695B2 (es)
KR (1) KR20100088621A (es)
CN (1) CN101970003A (es)
AU (1) AU2008323815B2 (es)
BR (1) BRPI0820407A2 (es)
CA (1) CA2705263A1 (es)
MX (1) MX2010005099A (es)
RU (1) RU2491095C2 (es)
WO (1) WO2009062054A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013106216A (ru) * 2010-08-03 2014-09-10 Ф. Хоффманн-Ля Рош Аг Биомаркеры хронической лимфоцитарной лейкемии
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19177059T1 (de) 2010-10-01 2021-10-07 Modernatx, Inc. N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
HUE065915T2 (hu) 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásaik
PT2688572T (pt) * 2011-03-21 2017-06-02 Valcuria Ab Composição farmacêutica com um inibidor de hdac e um esteroide e sua utilização
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE057725T2 (hu) 2011-10-03 2022-06-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
JP2015516143A (ja) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
UA122212C2 (uk) 2014-09-09 2020-10-12 Янссен Байотек, Інк. Вид комбінованої терапії з застосуванням антитіла до cd38
IL307913A (en) 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of acute myeloid leukemia
CN107249318A (zh) 2014-12-10 2017-10-13 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
WO2016115475A1 (en) * 2015-01-18 2016-07-21 Biogen Ma Inc. Anti-cd40 antibody formulations
MY198983A (en) 2015-05-20 2023-10-06 Janssen Biotech Inc Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
WO2016209921A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
KR20250007054A (ko) 2015-09-04 2025-01-13 프리마토프 테라퓨틱스 인크. 인간화 항-cd40 항체 및 그의 용도
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
SG11201803678SA (en) 2015-11-03 2018-05-30 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2025031434A1 (zh) * 2023-08-08 2025-02-13 北京志道生物科技有限公司 经修饰的细胞因子与cd40激动剂的联用组合物及其抗肿瘤用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1326896B1 (en) * 2000-10-02 2010-11-24 Novartis Vaccines and Diagnostics, Inc. Human anti-cd40 antibodies
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
JP5069843B2 (ja) * 2002-07-15 2012-11-07 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる処置に応答性である腫瘍を同定するための方法
ATE476991T1 (de) * 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verfahren zur behandlung von soliden tumoren mit expression des cd40-zelloberflächen-antigens
ATE474599T1 (de) * 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40- monoklonalen antikörpern zur behandlung von multiplem myelom
EP2149585B1 (en) * 2003-11-04 2013-08-14 Novartis Vaccines and Diagnostics, Inc. Use of antagonistic anti-CD40 monoclonal antibodies
EP1844815B1 (en) * 2003-11-04 2011-09-14 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
MXPA06012430A (es) * 2004-04-27 2007-04-19 Novartis Vaccines & Diagnostic Anticuerpos monoclonales antagonistas anti-cd40 y metodos para su uso.
US20060241076A1 (en) * 2005-04-26 2006-10-26 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
JP2009518441A (ja) * 2005-12-09 2009-05-07 シアトル ジェネティクス，インコーポレーテッド Ｃｄ４０結合剤の使用方法

Also Published As

Publication number Publication date
EP2211902A1 (en) 2010-08-04
CN101970003A (zh) 2011-02-09
CA2705263A1 (en) 2009-05-14
AU2008323815A1 (en) 2009-05-14
RU2491095C2 (ru) 2013-08-27
AU2008323815B2 (en) 2013-09-19
KR20100088621A (ko) 2010-08-09
BRPI0820407A2 (pt) 2015-05-26
US20110002934A1 (en) 2011-01-06
RU2010123363A (ru) 2011-12-20
JP5559695B2 (ja) 2014-07-23
WO2009062054A1 (en) 2009-05-14
JP2011503098A (ja) 2011-01-27

Similar Documents

Publication Publication Date Title
MX2010005099A (es) Usos de anticuerpos anti-cd40.
AR062840A1 (es) Terapia tumoral con una combinacion de anticuerpos anti receptor del factor de crecimiento epidermico (her2)
LTPA2022520I1 (es)
MX2009013656A (es) Composiciones terapeuticas anti-cd20 y metodos.
UA94899C2 (ru) Фиксированное дозирование антител к her
EA200970335A1 (ru) Композиции и способы для диагностики и лечения рака
JP2018534933A5 (es)
WO2007053661A3 (en) Uses of anti-cd40 antibodies
RU2010143454A (ru) Применение антитела к cd20 типа ii, обладающего повышенной антитело-обусловленной клеточнозависимой цитотоксичностью (adcc), в сочетании с циклофосфамидом, винкристином и доксорубицином для лечения не-ходжкинских лимфом
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
CY1112473T1 (el) Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
IL184617A0 (en) Dr5 antibodies and uses thereof
NZ590343A (en) Compositions monovalent for cd28 binding and methods of use
AU2006226733A8 (en) Antibodies against CD38 for treatment of multiple myeloma
EP4269563A3 (en) Anti-gd2 antibodies
EA201691747A1 (ru) Варианты комбинированной терапии с антителами анти-cd38
JO2576B1 (en) Antibodies
JP2017507954A5 (es)
SG170730A1 (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
UA109633C2 (uk) Антитіло людини проти тканинного фактора
IL187594A0 (en) Humanized anti-cd40 antibodies and their methods of use
NZ574978A (en) Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
FI3110440T3 (fi) Anti-cd38-vasta-aineita akuutin lymfaattisen leukemian hoitamiseksi
NZ705848A (en) Anti-cd38 antibodies
MX2009008510A (es) Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer.